Magnetofection磁转染试剂

Magnetofection PolyMAG/CombiMAG
MagnetoFACTOR plate 24 9008-24
MagnetoFACTOR plate 96 9008-26

Magnetofection™

Description

Magnetofection™ is a novel, simple and highly efficient method to transfect cells in culture. It exploits magnetic force exerted upon gene vectors associated with magnetic particles to draw the vectors towards, possibly even into, the target cells. In this manner, the full vector dose applied gets concentrated on the cells within a few minutes so that 100% of the cells get in contact with a significant vector dose. This has several important consequences:

Greatly improved transfection rates in terms of percentage of cells transfected compared to standard transfection.
Up to several thousand fold increased levels of transgene expression compared to standard transfections upon short-term incubation.
High transfection rates and transgene expression levels are achievable with extremely low vector doses, which allows to save expensive transfection reagents.
Extremely short process time. A few minutes of incubation of cells with gene vectors are sufficient to generate high transfection efficiency, compared to several hours with standard procedures.

Technology

Magnetofection™ Reagents

As the manufacturer of the Magnetofection™ technology, chemicell offers two types of ready-to-use Magnetofection™ reagents.

PolyMAG is a universally applicable magnetic particle preparation for high efficiency nucleic acid delivery. It is mixed in a one-step procedure with the nucleic acid to be transfected and has been used successfully with plasmid DNA, antisense oligonucleotides and siRNAs.

CombiMAG is a magnetic particle preparation designed to be combined with any commercially available transfection reagent such as polycations and lipids and can be associated with plasmid DNA, antisense oligonucleotides, siRNAs or viruses. It allows you to create your own magnetic gene vector based on your favourite transfection reagent.

Purchaser Notification
The Magnetofection™ reagents and all of its components are developed, designed, intended and sold for research use only. They are not to be used for human diagnostic or any drug intended.
Magnetofection™ are registered trademark

Nucleic Acids Dose Response and Transfection Kinetics

Transfection kinetics: NIH 3T3 cells were incubated with GenePorter™ (Gene Therapy Systems) ± CombiMAG with and without positioning on the MagnetoFACTOR plate for the indicated time spans. Luciferase expression was assayed after 24 hours.

	paramagnetic vehicle plus magnetic field
	paramagnetic vehicle no magnetic field
	standard gene transfer

Dose response profile in NIH 3T3 cells using Lipofectamine™ (Invitrogen) ± CombiMAG with and without positioning on the MagnetoFACTOR plate for 15 min. Luciferase expression was assayed after 24 hours.

top

Applications

Magnetofection™ is generally applicable for adherent cells and has been tested with a variety of immortalized cell lines and primary cells listed below. If a particular cell type or cell line is not listed this does not mean that Magnetofection™ would not work. Also for the cells listed, some reagents have not been tested so far, as indicated by "n.d." (not determined).

The CombiMAG reagent can be combined with any polycationic and lipidic transfection reagent, and also with adenoviral and retroviral vectors. In some cases, references are made in the footnotes to very successful combinations with commercially available reagents that have been tested so far.

Type of nucleic acid / virus	PolyMAG	CombiMAG
Plasmid DNA
Antisense Oligonucleotides
siRNA
Adenovirus	n.d.
Retrovirus	n.d.

Effectene (Qiagen)

Effectene + CombiMAG

Primary human umbilical vein endothelial cells positioned on the MagnetoFACTOR plate were incubated for 15 min with a Cy3 fluorescencelabeled antisense-oligonucleotide complexed with Effectene™ (Qiagen; left) or Effectene™ + CombiMAG (right).

(Data kindly provided by F. Kroetz. Ludwig-Maximilians University Munich)

Adherent cells
Cell Line	Cell Type	Source	PolyMAG	CombiMAG^*	Reference Number
HeLa	cervix carcinoma	human	+	+	9.030, 9.024, 9.072, 9.012, 9.111, 9.003, 9.005,9.016
HEK 293	kidney	human	+	+	9.013, 9.064, 9.054
BHK	kidney	hamster	n.d.	+	-
CHO	ovarian	hamster	+	+	9.036, 9.002, 9.005, 9.006
NIH 3T3	fibroblasts	mouse	+	+	9.003, 9.072, 9.091, 9.002, 9.005, 9.004
16HB140	airway epithelium	human	+	n.d.	9.010
EJ28	bladder cancer	human	+	n.d.	-
HBL-100	breast	human	n.d.	+	-
MCF7	breast adenocarcinoma	human	+	+	9.014, 9.040, 9.041, 9.115
MCS7	breast adenocarcinoma	human	+	n.d.	-
HCT 116	colon adenocarcinoma	human	n.d.	+	-
U373	astrocytoma	human	+	n.d.	9.056
U87	glioblastoma	human	+	n.d.	9.056
U251	glioblastoma	human	+	n.d.	9.056
T98G	glioblastoma	human	+	n.d.	9.056
YK6-1	glioblastoma	human	+	n.d.	9.056
YH-13	glioblastoma	human	+	n.d.	9.056
A549	alveolar basal epithelial	human	+	+	9.075, 9.101
A172	glioblastoma	human	+	n.d.	9.056, 9.074
LN229	glioblastoma	human	+	+	9.074
LN18	glioblastoma	human	+	+	9.074
SW480	colon adenocarcinoma	human	n.d.	+	-
LoVo	colon adenocarcinoma	human	n.d.	+	-
HCT15	colon adenocarcinoma	human	n.d.	+	-
CEMx174	hybrid T/B-lymphocytes	human	n.d.	+	9.060
CHO	ovarian	human	+	+	-
A431	epidermoid carcinoma	human	n.d.	+	-
HT-1080	fibrosarcoma	human	+	n.d.	-
HFF	foreskin fibroblast	human	+	+	-
Hep G2	hepatocellular carcinoma	human	+	+	9.012, 9.048
HaCat	keratinocytes	human	n.d.	+	-
293 T	kidney	human	+	+	9.030
293 T-17	kidney	human	n.d.	+	9.030
SK-MES-1	lung carcinoma	human	+	n.d.	-
MRC 5	lung, embryonic	human	+	+	-
MeWo	melanoma	human	n.d.	+	-
NYGM	cerebral glioblastoma	human	n.d.	+	9.056
SK-MEL-28	melanoma	human	n.d.	+	-
MEP	mammalian epithelial	human	n.d.	+	9.047
MOLT-4	acute lymphoblastic leukemia	human	n.d.	+	9.044
SHSY-5Y	neuroblastoma	human	n.d.	+	9.111, 9.050
SV40	transformed fibroblasts	human	+	n.d.	9.027
A549	Non-small cell lung carcinoma	human	n.d.	+	9.057, 9.101
SaOS-2	osteo sarcoma	human	n.d.	+	-
BTK-143	osteo sarcoma	human	n.d.	+	-
BEAS-2B	lung epithelial cells	human	+	n.d.	9.012
181RDB	pancreatic	human	n.d.	+	-
HN12	Head, neck carcinoma	human	n.d.	+	9.028
PC-3	prostate carcinoma	human	n.d.	+	-
H9	lymphoblastoid	human	n.d.	+	9.077
H295R	adrenocortical carcinoma	human	n.d.	+	9.058, 9.059, 9.037
HOS	osteosarcoma	human	n.d.	+	9.077
HSG	salivary gland, submandibular	human	n.d.	+	-
He99	lung cancer	human	+	+	9.100
HMEC-1	microvascular endothelial	human	+	n.d.	9.038, 9.092
NCI-H441	lung adenocarcinoma epithelial	human	+	+	9.073
NCI-H292	mucoepidermoid carcinoma	human	+	n.d.	9.065, 9.095, 9.112
NCI-H82	small cell lung cancer	human	+	n.d.	-
SK-N-BE2	neuroblastoma	human	+	n.d.	9.031
MDAMB231	breast adenocarcinoma	human	+	n.d.	9.035
ECV-304	urinary bladder carcinoma	human	n.d.	+	-
11.5dpcXY	gonad explants	mouse	n.d.	+	9.109
Cal27	oral adenosquamous carcinoma	mouse	n.d.	+	9.028
CT-26	colon carcinoma	mouse	+	n.d.	9.003, 9.005
C127	murine mammary tumor	mouse	n.d.	+	9.042
F9	embryonal carcinoma	mouse	+	n.d.	-
L929	fibroblast, connective tissue	mouse	+	n.d.	9.016
MEF	fibroblast	mouse	+	n.d.	9.039, 9.098
HT-22	hippocampal neuroblast	mouse	n.d.	+	-
mIEnd	Mesenteric lymph node	mouse	n.d.	+	9.085
mIC-(cl2)	intestine	mouse	n.d.	+	-
B16F10	melanoma	mouse	+	n.d.	9.076, 9.005
N2a	neuroblastoma	mouse	+	n.d.	9.063, 9.086
NS20Y	neuroblastoma	mouse	n.d.	+	-
bTC-tet	B-cell line	mouse	+	+	9.020
Hepa1c1c7	murine hepatoma	mouse	+	n.d.	9.084
SVEC	murine cell line	mouse	n.d.	+	9.028
OP9	bone marrow-derived stromal	mouse	n.d.	+	9.047
SM 10	trophoblast	mouse	n.d.	+	-
STC-1	enteroendocrine I cells	mouse	+	+	9.033
A7r5	aortic smooth muscle	rat	n.d.	+	9.094
PC12	adrenal pheochromocytoma	rat	+	n.d.	-
PC6-3	daughter cell line of PC12	rat	+	n.d.	-
C6	glioma	rat	n.d.	+	-
H4IIE	hepatoma	rat	n.d.	+	9.062
L6	skeletal muscle cell	rat	+	n.d.	-
RIE1-α5	intestinal	rat	+	n.d.	9.088
HNSCC	Head, neck carcinoma	rat	n.d.	+	9.015, 9.028, 9.051
RV	vein	rat	+	n.d.	-
COS-7	kidney	monkey	+	+	9.030
CV-1	kidney	monkey	+	n.d.	-
COS-1	kidney	monkey	n.d.	+	-
Vero	kidney	monkey	n.d.	+	9.045, 9.046, 9.016
B11	(UV) resistant ovary	hamster	n.d.	+	9.028
V79	lung fibroblasts	hamster	+	n.d.	-
PT-11	kidney	bovine	n.d.	+	-
MDCK	kidney	canine	+	n.d.	9.067
CRFK	kidney	cat	n.d.	+	-
VSa13	bone (chondrocyte-like)	fish	+	n.d.	-
AM-C6SC8	kidney	pig	n.d.	+	-
-	fibroblasts	xenopus	+	n.d.	-
EMC	mesenthelial. Cells (epicard)		n.d.	+	-

Suspension cells
Cell Line	Cell Type	Source	PolyMAG	CombiMAG^*	Reference number
THP-1	acute myeloid leukemia	human	n.d.	+	-
Jurkat	acute T-cell lymphoma	human	n.d.	+	9.044, 9.073
BL-41	B-cell lymphoma	human	+	n.d.	-
K562	chronic myeloid lymphoma	human	n.d.	+	9.002
P815	mastocytoma	mouse	n.d.	+	-
U937	histiocytic lymphoma	human	+	+	-

Primary cells
Cell Type		Source	PolyMAG	CombiMAG^*	Reference Number
endothelial cells (cord blood)		human	+	n.d.	9.054
aortic endothelial cells		human	+	n.d.	9.028, 9.032
epithelial (HUVEC)		human	+	n.d.	9.029, 9.034, 9.092, 9.113, 9.114, 9.003, 9.007,9.008, 9.021, 9.029, 9.034, 9.005, 9.004
fibroblasts		human	+	+	-
fibroblasts, diploid		human	+	+	-
gastric gland		human	+	+	-
adherent gastric cells		human	n.d.	+	9.069
gastric myofibroblasts		human	+	n.d.	9.043
glioma		human	+	n.d.	-
keratinocytes		human	n.d.	+	9.005
LNCaP		human	n.d.	+	-
lymphocytes		human	+	+	9.005, 9.102
mammal epithelium		human	n.d.	+	-
nasal airway epithelium		human	+	+	9.005
pancreatic tumor		human	+	n.d.	-
peripheral blood lymphocytes		human	+	+	9.005, 9.102
stroma cells (endometrium)		human	n.d.	+	-
T-cells		human	+	n.d.	9.102, 9.089
chondrocytes		human	+	+	9.107, 9.022, 9.024
trophoblastic cells		human	n.d.	+	-
fibroblasts (MEF)		mouse	n.d.	+	9.018, 9.053
neurons		mouse	+	+	9.071
vagal afferent neurons		mouse	n.d.	+	9.071
adherent gastric cells		mouse	n.d.	+	9.061
peripheral blood lymphocytes		mouse	n.d.	+	-
myoblasts		mouse	n.d.	+	9.053
T-cells		mouse	+	n.d.	-
hippocampal neurons		rat	+	+	9.017, 9.070, 9.050, 9.052, 9.093, 9.090, 9.105,9.104
aortic smooth muscle cells		rat	n.d.	+	9.094
cardiomyocyte		rat	n.d.	+	9.055
hepatocytes		rat	n.d.	+	-
epithelial (HUVEC)		rat	+	+	9.028, 9.054
cortical neurons		rat	n.d.	+	9.052, 9.063, 9.097
aortic endothelial cells		bovine	+	n.d.	-
carotid artery smooth muscle		bovine	+	n.d.	-
chromaffine cells		bovine	n.d.	+	-
lens		bovine	+	n.d.	-
airway epithelium		pig	n.d.	+	-
chondrocytes		pig	+	+	-
fibrochondrocytes		pig	+	+	-
pSM, smooth muscle		pig	n.d.	+	-

^* Corresponds to successfully transfected by CombiMAG in association with different commercial transfection reagents such as FuGENE™ (Roche), Lipofectamine™, METAFECTENE™ (Biontex GmbH) and DMRIE-C™ (Invitrogen); adenovirus; Effectene™ (Qiagen)

n.d. = not determined

top

Available Kits

Product Number	Description	Size (sufficient for n µg DNA)	Number of transfections (96-well format)
9001	PolyMAG-100	100	1000
9002	PolyMAG-500	500	5000
9003	PolyMAG-1000	1000	10000

9004	CombiMAG-100	100	500
9005	CombiMAG-500	500	2500
9006	CombiMAG-1000	1000	5000

9007	MagnetoFACTOR plate 96

9009	MagnetoFACTOR plate 24

9008-96	SPECIAL OFFER: MagnetoFACTOR-96 plate PolyMAG-200 CombiMAG-200	200 200	2000 1000
9008-24	SPECIAL OFFER: MagnetoFACTOR-24 plate PolyMAG-200 CombiMAG-200	200 200	2000 1000

Storage:
All components of the Magnetofection™ kit should be stored at room temperatur (20-25°C). After first use store the kit at +4°C.

Do not freeze the magnetic nanoparticles
Do not add anything to the stock solution of magnetic nanoparticles
Shipping Conditions: Room Temperatur

MagnetoFACTOR-96 plate

MagnetoFACTOR-24 plate

The MagnetoFACTOR-96 plate its special geometry not only produces strong magnetic fields under each well of 96-well plates but is also applicable for other plate formats T-75 culture flasks, 6- and 12-well plates. In the larger plate formats, the MagnetoFACTOR plate will produce a pattern of higher and lower densities of transfected cells according to the geometry of the magnetic field lines. The MagnetoFACTOR-24 plate is special designed for the 24-well format.

首页 ꄲ 代理品牌 ꄲ Magnetofection磁转染试剂

搜索